InMed Pharmaceuticals Inc. (INM) News

InMed Pharmaceuticals Inc. (INM): $0.49

0.00 (0.02%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add INM to Watchlist
Sign Up

Industry: Biotech


Ranked

of 470

in industry

Filter INM News Items

INM News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

INM News Highlights

  • For INM, its 30 day story count is now at 6.
  • Over the past 6 days, the trend for INM's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • The most mentioned tickers in articles about INM are RARE, CBT and DRUG.

Latest INM News From Around the Web

Below are the latest news stories about InMed Pharmaceuticals Inc that investors may wish to consider to help them evaluate INM as an investment opportunity.

InMed Pharmaceuticals Inc. (INM) CEO Eric Adams on Q2 2022 Results - Earnings Call Transcript

InMed Pharmaceuticals Inc. (INM) Q2 2022 Earnings Conference Call February 15, 2022 14:00 ET Corporate Participants Colin Clancy - Senior Director of Investor Relations Eric Adams - President and Chief Executive Officer Bruce Colwill - Chief Financial Officer Eric Hsu - Senior Vice President, Preclinical Research and Development Alexandra Mancini...

SA Transcripts on Seeking Alpha | February 16, 2022

InMed Pharmaceuticals (INM): Generating Commercial Sales of CBC and CBT

LONDON, UK / ACCESSWIRE / February 16, 2022 / InMed Pharmaceuticals' (INM's) Q222 financial results reflect its evolution from a pure-play biotech firm to one with commercial sales to the health and wellness market, with revenues of $0. As of January, it also began selling cannabicitran (CBT) to the health and wellness market.

Yahoo | February 16, 2022

InMed Pharmaceuticals Strengthens its Commercial Leadership Team with the Appointment of Vice President of Sales and Marketing for BayMedica

VANCOUVER, British Columbia, Feb. 15, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce the appointment of Gerard (Jerry) P. Griffin III as Vice President of Sales and Marketing at BayMedica, a wholly owned subsidiary of InMed. Mr. Griffin will oversee the commercialization of BayMedica’s health and wellness business including the exi

Yahoo | February 15, 2022

InMed Pharmaceuticals Inc. (INM) Reports Q2 Loss, Tops Revenue Estimates

InMed Pharmaceuticals Inc. (INM) delivered earnings and revenue surprises of -29.17% and 6%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 15, 2022

InMed Pharmaceuticals Reports Second Quarter Fiscal 2022 Financial Results and Provides Business Update

Completed acquisition of BayMedica, a rare cannabinoid manufacturing and commercialization company in the health and wellness sectorStrengthened IP with patent filing for use of rare cannabinoids for the treatment of neurodegenerative diseasesCommercial rollout of an additional rare cannabinoid, CBT- first of several rare cannabinoid launches planned for the first half of 2022Advanced the pharmaceutical drug development programs in EB, glaucoma and neurodegenerative diseases VANCOUVER, British C

Yahoo | February 15, 2022

InMed Pharmaceuticals to Report Second Quarter Fiscal 2022 Financial Results and Business Update on February 15, 2022

VANCOUVER, British Columbia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, will report financial results on Tuesday, February 15, 2022 for the second quarter of fiscal year 2022, ending December 31, 2021. Conference Call & Webcast*:Tuesday, February 15, 2022, at 11:00 AM Pacific Time, 02:00 PM Eastern TimeUS/CANADA Participant Toll-Free Dial-In

Yahoo | February 10, 2022

InMed launches B2B sales of rare cannabinoid cannabicitran

InMed Pharmaceuticals <> launched B2B sales of rare cannabinoid cannabicitran ((CBT)) into the health and wellness sector.The company said CBT is the first of several…

Seeking Alpha | January 19, 2022

InMed Launches Cannabicitran (CBT), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector

CBT is the first of several rare cannabinoid launches planned for the first half of 2022; includes CBDV and THCVExpands the Company’s rare cannabinoid product portfolio, which also includes cannabichromene (CBC)Strengthens leadership position in commercial scale production of high demand rare cannabinoids VANCOUVER, British Columbia, Jan. 19, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and comm

Yahoo | January 19, 2022

InMed Pharmaceuticals'' Issues Annual Shareholder Letter

InMed Pharmaceuticals (NASDAQ: INM ), a leader in the development, manufacturing, and commercialization of rare cannabinoids, has released a shareholder letter. The letter, from president and CEO Eric A. Adams, provided INM shareholders with a company update, including a look at key milestones the company had reached, including the acquisition of BayMedica, which Adams said positioned InMed as a clear leader in rare cannabinoid manufacturing. Adams also noted that the company continued to make significant strides with its proprietary IntegraSyn(TM) program and is advancing its pharmaceutical programs, thanks in large part to the library of novel cannabinoid analogs developed by BayMedica. The company also initiated a phase 2 trial of its INM-755 program for the treatment of epidermolysi...

Benzinga | January 5, 2022

InMed Issues Annual Letter to Shareholders Highlighting Key Accomplishments from 2021 and Providing 2022 Outlook

VANCOUVER, British Columbia, Jan. 05, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, today issued the following letter from President and CEO Eric A. Adams. Dear Shareholders, Colleagues, and Business Partners, I’d like to start off by sending you warm wishes for a healthy and prosperous 2022. While another wave of the COVID-19 pandemic continues to bring global u

Yahoo | January 5, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5703 seconds.